Home >> Tag Archives: Roche—

Tag Archives: Roche—

Why DMTs are a critical ingredient in the delivery of value-based care

Webinar presenters Michael Laposata, MD, PhD, University of Texas Medical Branch at Galveston Pathology, Chairman, and Bruce Friedman, MD, University of Michigan, Pathology, Emeritus Professor, Informatics, discuss the barriers that exist for the rapid and significant growth of diagnostic management teams to reduce medical error and optimize laboratory test use, overcoming barriers to DMT implementation, addressing connectivity between experts and doctors, and identifying ways to overcome DMT resistance from your peers. This on-demand webinar was hosted before a live audience at DMT Conference Galveston Island Convention Center, Galveston, Texas, on March 5, 2019.

Read More »

Roche launches IVD pan-TRK IHC assay

Nov. 29, 2018—Roche announced the worldwide launch of the Ventana pan-TRK (EPR17341) Assay, an automated in vitro diagnostic immunohistochemistry assay to detect tropomyosin receptor kinase proteins in cancer. The CE IVD/U.S. class I assay is designed to detect C-terminal protein expression, which allows for the detection of TRK-fusion as well as wild-type protein expression. “As the first test of its kind, ...

Read More »

Study: Kadcyla improved invasive disease-free survival

November 2018—Roche announced the phase three KATHERINE study met its primary endpoint, showing Kadcyla (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival) compared with trastuzumab as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment.

Read More »

Roche announces availability of FoundationOne Liquid

Sept. 27, 2018—Roche announced that its FoundationOne Liquid, a blood-based genomic profiling test, is available worldwide. FoundationOne Liquid can identify circulating tumor DNA in the blood of people with cancer and can identify 70 of the most commonly mutated genes in solid tumors, including microsatellite instability.

Read More »

MU School of Medicine, Roche team up

September 2018—Roche announced the result of a collaboration with the University of Missouri School of Medicine to implement the company’s Navify tumor board solution, cloud-based clinical workflow and decision-support software to assist with cancer patient case reviews in tumor board and multidisciplinary team meetings.

Read More »

FDA approves Cobas HPV Test with SurePath

Aug. 3, 2018—Roche has received FDA approval for the Cobas HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using specimens collected in SurePath preservative fluid. The Roche test is now the only HPV test approved for use as a primary screening test with both SurePath and ThinPrep PreservCyt Solution. It ...

Read More »

Roche buys remainder of Foundation Medicine

June 25, 2018—Roche and Foundation Medicine have entered into a merger agreement for Roche to acquire the outstanding shares of FMI’s common stock not already owned by Roche for $2.4 billion. The companies will focus on using FMI’s comprehensive genomic profile testing to develop treatments for patients with cancer. Foundation Medicine will continue to operate independently. “This is important to ...

Read More »